dc.contributor.author | Patel, Ashaben | |
dc.contributor.author | Gupta, Vineet | |
dc.contributor.author | Hickey, John M. | |
dc.contributor.author | Nightlinger, Nancy S. | |
dc.contributor.author | Rogers, Richard S. | |
dc.contributor.author | Siska, Christine | |
dc.contributor.author | Joshi, Sangeeta B. | |
dc.contributor.author | Seaman, Michael S. | |
dc.contributor.author | Volkin, David B. | |
dc.contributor.author | Kerwin, Bruce A. | |
dc.date.accessioned | 2020-11-30T14:58:39Z | |
dc.date.available | 2020-11-30T14:58:39Z | |
dc.date.issued | 2018-12-01 | |
dc.identifier.citation | Patel, A., Gupta, V., Hickey, J., Nightlinger, N. S., Rogers, R. S., Siska, C., Joshi, S. B., Seaman, M. S., Volkin, D. B., & Kerwin, B. A. (2018). Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies. Journal of pharmaceutical sciences, 107(12), 3032–3046. https://doi.org/10.1016/j.xphs.2018.08.012 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/30934 | |
dc.description | This work is licensed under a Creative Commons Attribution 4.0 International License. | en_US |
dc.description.abstract | In this study, we investigated analytical challenges associated with the formulation of 2 anti-HIV broadly neutralizing antibodies (bnAbs), 3BNC117 and PGT121, both separately at 100 mg/mL and together at 50 mg/mL each. The bnAb formulations were characterized for relative solubility and conformational stability followed by accelerated and real-time stability studies. Although the bnAbs were stable during 4°C storage, incubation at 40°C differentiated their stability profiles. Specific concentration-dependent aggregation rates at 30°C and 40°C were measured by size exclusion chromatography for the individual bnAbs with the mixture showing intermediate behavior. Interestingly, although the relative ratio of the 2 bnAbs remained constant at 4°C, the ratio of 3BNC117 to PGT121 increased in the dimer that formed during storage at 40°C. A mass spectrometry-based multiattribute method, identified and quantified differences in modifications of the Fab regions for each bnAb within the mixture including clipping, oxidation, deamidation, and isomerization sites. Each bnAb showed slight differences in the levels and sites of lysine residue glycations. Together, these data demonstrate the ability to differentiate degradation products from individual antibodies within the bnAb mixture, and that degradation rates are influenced not only by the individual bnAb concentrations but also by the mixture concentration. | en_US |
dc.description.sponsorship | Bill and Melinda Gates Foundation, Seattle, WA [grant number OPP1138851 and Investment ID 25617] | en_US |
dc.publisher | Wiley | en_US |
dc.rights | © 2018 Published by Elsevier Inc. on behalf of the American Pharmacists Association. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Broadly neutralizing antibodies | en_US |
dc.subject | Stability | en_US |
dc.subject | Coformulation | en_US |
dc.subject | Mass spectrometry | en_US |
dc.subject | Protein aggregation | en_US |
dc.subject | Calorimetry (DSC) | en_US |
dc.subject | Capillary electrophoresis | en_US |
dc.subject | Deamidation | en_US |
dc.subject | Oxidation | en_US |
dc.subject | Biotechnology | en_US |
dc.title | Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Patel, Ashaben | |
kusw.kuauthor | Gupta, Vineet | |
kusw.kuauthor | Hickey, John M. | |
kusw.kuauthor | Joshi, Sangeeta B. | |
kusw.kuauthor | Volkin, David B. | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
kusw.oanotes | Per Sherpa Romeo 11/30/2020:
Journal of Pharmaceutical Sciences
[Open panel below]Publication Information
TitleJournal of Pharmaceutical Sciences [English]
ISSNs
Print: 0022-3549
Electronic: 1520-6017
URLhttp://www.jpharmsci.org/
Publishers
Wiley [Former Publisher]
American Pharmacists Association [Associate Organisation]
Elsevier [Commercial Publisher]
Published Version
[pathway b] NoneCC BY
Institutional Repository, Subject Repository, PMC, Research for Development Repository, +2
OA FeeThis pathway has an Open Access fee associated with it
OA PublishingThis pathway includes Open Access publishing
EmbargoNo Embargo
LicenceCC BY
Location
Institutional Repository
Named Repository (PubMed Central, Research for Development Repository, ESRC Research Catalogue)
Subject Repository
Journal Website
ConditionsPublished source must be acknowledged with citation | en_US |
dc.identifier.doi | 10.1016/j.xphs.2018.08.012 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC6269598 | en_US |
dc.rights.accessrights | openAccess | en_US |